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ABSTRACT
Addiction is a complex process in which behavioral sensitization may be
an important component. While the behavioral effects of sensitization are well
established, the intricate neurobiology of the phenomenon is still largely
unknown. Dopamine systems mediate the induction of behavioral sensitization in
adult rats, but there is a large amount of evidence showing that other
neurotransmitter systems also modulate the induction process. For example, the
α1b-adrenergic and 5-HT2A receptor systems are known to modulate the
sensitized responding of adult rats, but the roles that these receptor systems play
in the induction and expression of behavioral sensitization during the preweanling
period has yet to be investigated. Therefore, the purpose of this thesis was to
determine whether the serotonergic and adrenergic receptor systems mediate
the induction and/or expression of cocaine-induced one-trial behavioral
sensitization in preweanling rats. I used a novel approach to address this
question, as the receptors of interest were “protected” from the alkylating effects
of EEDQ (an irreversible nonselective receptor antagonist) by prior treatment
with selective antagonist drugs. More specifically, rats were given ritanserin (a
serotonergic receptor antagonist), prazosin (an adrenergic receptor antagonist),
or a combination of the two drugs prior to an injection of EEDQ. To study the
induction of behavioral sensitization, this series of injections was administered on
PD 18 (24 h before the pretreatment injection of cocaine). To study the
expression of behavioral sensitization, the injections were administered on PD
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20, which was the day between the drug pretreatment day and the test day. In all
experiments, the test day (i.e., the day on which the challenge dose of cocaine
was given) was on PD 21. Control experiments were performed for both the
induction and expression paradigms in order to determine whether prazosin and
ritanserin independently affected sensitization. Results showed that the receptor
inactivation caused by EEDQ blocked both the induction and expression of
cocaine-induced one-trial behavioral sensitization. Importantly, administering
prazosin and ritanserin did not protect the induction of the sensitized locomotor
response, which suggests that serotonergic and adrenergic receptors do not
mediate cocaine-induced one-trial behavioral sensitization in preweanling rats.
This conclusion should be tempered, however, because co-administration of
prazosin and ritanserin affected the locomotor activity and sensitized responding
of cocaine-treated rats independent of the actions of EEDQ. Considering both
past and present results, the most harmonious conclusion is that multiple
receptor systems (i.e., dopaminergic, serotonergic, adrenergic, etc.) work in
unison to produce the complex phenomenon of behavioral sensitization.
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CHAPTER ONE
MODEL OF ADDICTION

Psychostimulants possess highly addictive qualities and can have
many complex and detrimental health effects, thus constituting a serious
public health concern. The acutely rewarding properties of psychostimulants,
such as cocaine and the amphetamines, often lead to compulsive use
(Hyman, 1996). In addition, drug users report many adverse effects such as
anxiety, depression, mood swings, paranoia, and panic attacks, as well as
sleep and appetite disturbances (Williamson, Gossop, Powis, Griffiths,
Fountain, & Strang, 1997).
Addiction is a complex process in which behavioral sensitization may
be an important component (Robinson & Berridge, 1993). In animals,
behavioral sensitization is observed as a progressive increase in behavioral
responsiveness after repeated treatment with a psychostimulant drug (Kalivas
& Stewart 1991; Robinson & Becker, 1986). In animal models, sensitization is
often described in terms of drug-induced changes in locomotor activity or
stereotyped movement. For example, many studies have reported increased
locomotor activity after a challenge dose of psychostimulant (Duke, O’Neil, &
McDougall, 1997; Kalivas & Stewart, 1991; Kolta, Shreve, De Souza, &
Uretsky, 1985; Leith & Kuczenski, 1982; McDougall, Duke, Bolanos, &
Crawford, 1994; Robinson & Becker, 1986). In addition, rats given repeated
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injections of cocaine exhibit increased stereotypy when challenged with a
high dose of cocaine (Kuczenski & Segal, 1999; Kuczenski, Segal, &
Aizenstein, 1991; Wood, Tirelli, Snyder, Heyser, LaRocca, & Spear, 1998).
Although many studies have used animal models to examine
psychostimulant-induced behavioral sensitization, the number of studies
investigating sensitization in humans is limited. The few studies that have
been done in humans have produced generally positive findings. For
instance, when participants were given two twice-daily doses of amphetamine
one day apart, eye-blink rate, energy level, mood, and rate and amount of
speech increased (Strakowski, Sax, Setters & Keck, 1996). In another study,
after being given three doses of amphetamine (0.25 mg/kg) at 48 h intervals,
a progressive increase in eye-blink, mood, energy level, motor activity, and
speech was observed after each administration of the drug (Sax &
Strakowski, 1998). Further investigation of this phenomenon lead to the
finding that mood elevation was affected by characteristics of the participant
personality, namely neophilia (Sax & Strakowski, 1998; Strakowski, Sax,
Rosenberg, DelBello, & Adler, 2001). Boileau et al. (2006) concluded that the
observed increases in mood, as well as changes in underlying neural
mechanisms, were consistent with the behavioral and neurochemical effects
occurring in animal sensitization.
While the behavioral effects of sensitization are well established, the
complex neurobiology of the phenomenon is still largely unknown. It has long
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been recognized that the dopamine system is critically involved in mediating
reward (Bozarth, 1986). Therefore, it is not surprising that dopaminergic
pathways are also implicated in the induction of psychostimulant-induced
behavioral sensitization. This is perhaps best illustrated by studies using
nonselective or selective dopamine receptor antagonists (Kuribara &
Uchihashi, 1993; Vezina & Stewart, 1989). Specifically, pretreating rats or
mice with dopamine antagonists often blocks the induction of
methamphetamine and cocaine sensitization.
Compared to adults, adolescents are more vulnerable to developing a
drug addiction (Schramm-Sapyta, Walker, Caster, Levin, & Kuhn, 2009;
Spear, 2000), yet relatively few behavioral sensitization studies have been
conducted in young rats (for reviews, see Laviola, Adriani, Terranova, &
Gerra, 1999; Tirelli, Laviola, & Adriani, 2003). In fact, initial reports suggested
that young rats do not exhibit behavioral sensitization (Fujiwara, Kazahaya,
Nakashima, Sato, & Otsuki, 1987; Kolta, Scalzo, Ali, & Holson, 1990). Recent
studies show that behavioral sensitization will occur in young rats, although
the behavioral sensitization of young rats is often weaker and endures for a
more limited period of time than in adults (McDougall et al., 1994; Wood et al.,
1998; Zavala, Nazarian, Crawford, & McDougall, 2000). Importantly, these
differences in the manifestation of behavioral sensitization are specific to the
multi-trial paradigm. In one-trial sensitization, where testing occurs one or
more days after a single administration of psychostimulant, the sensitized
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response is equally robust in young and adult rats (McDougall, Baella,
Stuebner, Halladay, & Crawford, 2007; McDougall, Cortez, Palmer, Herbert,
Martinez, Charntikov, & Amodeo, 2009).
In addition to ontogenetic differences in the behavioral manifestation of
sensitization, there is evidence that the underlying neural mechanisms
responsible for sensitization also change throughout development. For
example, dopamine D1-like and D2-like receptor stimulation is necessary for
the induction of one-trial cocaine-induced behavioral sensitization in adult rats
(Fontana, Post, Weiss, & Pert, 1993; Valjent, Bertran-Gonzalez, Aubier,
Greengard, Hervé, & Girault, 2010; Weiss, Post, Pert, Woodward, & Murman,
1989). In contrast, D1-like and D2-like receptor antagonists do not block the
methamphetamine- or cocaine-induced behavioral sensitization of
preweanling rats (Mohd-Yusof, Gonzalez, Veliz, & McDougall, 2014; MohdYusof, Veliz, Rudberg, Stone, Gonzalez, & McDougall, 2016). The latter
results suggest that the induction of behavioral sensitization in young rats is
mediated by non-dopaminergic receptor systems.
Although dopamine systems are known to mediate the induction of
behavioral sensitization in adult rats, there is a large amount of evidence
showing that other neurotransmitter systems also modulate the induction
process. For example, Auclair, Drouin, Cotecchia, Glowinski, and Tassin
(2004) reported that blocking α1b-adrenergic and 5-HT2A receptors partially
attenuated morphine-, cocaine-, and amphetamine-induced behavioral
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sensitization. Importantly, combined treatment with α1b-adrenergic and 5HT2A receptor antagonists fully attenuated the induction of cocaine- and
amphetamine-induced behavioral sensitization in adult mice (Auclair et al.,
2004).
In young rats, the involvement of α1b-adrenergic and 5-HT2A receptor
systems in the induction of behavioral sensitization had not been investigated.
Because the dopamine system does not mediate the induction of behavioral
sensitization in young rats, and antagonists at α1b-adrenergic and 5-HT2A
receptors attenuate the induction process in adults, I hypothesized that the
serotonergic and adrenergic systems mediate the induction of behavioral
sensitization at earlier ages. In summary, the purpose of this thesis was to
determine whether the serotonergic and adrenergic systems mediate the
induction of cocaine-induced one-trial behavioral sensitization during the
preweanling period. The results of this study provide additional knowledge
about the relationship between neurotransmitter systems underlying
behavioral sensitization, and increase our understanding of the addiction
process.
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CHAPTER TWO
THE DOPAMINE SYSTEM

Introduction
Catecholamines, such as epinephrine, norepinephrine and dopamine,
are organic compounds that derive from the amino acid tyrosine (Kujar,
Couceyro, & Lambert, 1999). Of the catecholamines in the central nervous
system, dopamine is the most abundant. Dopamine is characterized by a
single amine group, a central molecule of benzene, ethylamine, and hydroxyl
groups named “catechol” (Feldman, Meyer, & Quenzer, 1997). Reward,
movement, emotion, and neuroendocrine secretion are a few of the major
functions regulated by dopamine (Jaber, Robinson, Missale, & Caron, 1996).
Because of its important role in the function of the central nervous system,
dopamine dysregulation leads to a number of neuropsychiatric disorders. For
example, neurodegeneration of the dopamine system can lead to Parkinson’s
Disease, whereas imbalance and dysfunction within the dopamine system
plays a role in addiction and schizophrenia.
George Barger and James Ewens first synthesized dopamine in 1910
at Wellcome Laboratories in London, England (Levite, 2012). However,
dopamine was not discovered to be a neurotransmitter until 1958 by Arvid
Carlsson and Nils-Ake Hillarp in Sweden (Carlsson, Lindqvist, Magnusson, &
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Waldeck, 1958). Until this time, dopamine was only thought to be a precursor
for norepinephrine and epinephrine.

Dopamine Synthesis
The initial step in the synthesis of dopamine is the conversion of Ltyrosine to L-dihydroxyphenylalanine (L-DOPA) in a reaction catalyzed by
tyrosine hydroxylase (Nagatsu, Levitt, & Udenfriend, 1964). The enzyme
aromatic amino acid decarboxylase then catalyzes L-DOPA into dopamine
(Roth, 1979; Sourkes, 1979). The rate limiting step in the production of
dopamine is the availability of tyrosine hydroxylase, which is regulated by
multiple feedback mechanisms (Binder, Kinkead, Owens, & Nemeroff, 2001).
Dopamine production occurs in the presynaptic terminals of dopaminergic
neurons. Following synthesis, dopamine is packaged into synaptic vesicles
via a transporter protein generated proton gradient and released via calciumdependent exocytosis (Binder et al., 2001). Dopamine can be released either
tonically or phasically (Keeler, Pretsell, & Robbin, 2014).

Dopaminergic Pathways
There are four major pathways that make up the dopaminergic system;
the nigrostriatal, mesolimbic, mesocortical, and the tuberoinfundibular
pathways. As the name implies, the nigrostriatal pathway originates in the
substantia nigra pars compacta, and terminates in the striatum. This pathway
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is primarily involved in the regulation of motor movement (Geffen, Jessell,
Cuello, & Iverrson, 1976; Huang, Zhou, Chase, Gusella, Aronin, & DiFiglia,
1992). The mesolimbic pathway, which is known as the “reward pathway”,
begins in the ventral tegmental area (VTA) and terminates in the nucleus
accumbens (Chang & Kitai, 1985). The cell bodies of neurons in the
mesocortical pathway, which is involved in motivation and emotion, are
located in the VTA, and the axons project to the prefrontal cortex (Carr &
Sesack, 2000; Lewis & O’Donell, 2000; Seamans, Floresco, & Phillips, 1998).
Finally, the tuberoinfundibular pathway projects from the hypothalamus to the
posterior pituitary. Because of its role in mediating pituitary function, this
pathway modulates the secretion of hormones (Ben-Jonathan, 1985; Leong,
Frawley, & Neill, 1983; Sawai, Iijima, Ozawa, & Matsuzaki, 2014). As is
suggested by the involvement of dopamine in these major pathways,
dopamine is an important neurotransmitter that is crucial to normal functioning
of the brain.

Classification of Dopamine Receptors
Dopamine receptors are categorized into two families: D1-like
receptors and D2-like receptors. These families can be further subdivided into
individual subtypes. Both D1 and D5 receptor subtypes are members of the
D1-like family, whereas D2, D3, and D4 receptors are part of the D2-like family.
All dopamine receptors are coupled to G proteins (Keeler et al., 2014).
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D1-Like Receptors
D1-like receptors are generally excitatory (Keeler et al., 2014). These
receptors are coupled to Gs complexes that, when stimulated, increase the
activity of adenylyl cyclase. This action, in turn, increases the production of
cyclic AMP (Kebabian et al., 1984; Roberts-Lewis, Roseboom, Iwaniec, &
Gnergy, 1986). D1 and D5 receptors have a low affinity for dopamine, causing
them to be more sensitive to changes in phasic dopamine release (Dreyer,
Herrik, Berg, & Hounsgaard, 2010; Kebabian et al., 1984).
Generally speaking, D1-like receptors are more abundant in brain than
D2-like receptors (Boyson, McGonigle, & Molinoff, 1986). The D1 subtype
differs from the D5 subtype in its distribution throughout the brain. In-situ
hybridization, a technique used to detect gene expression in individual cells,
shows that D1 receptors are primarily found in the caudate-putamen, nucleus
accumbens, thalamus, hypothalamus, and olfactory tubercle (Fremeau,
Duncan, Fornaretto, Dearry, Gingrich, Breese, & Caron, 1991).
Autoradiography shows that D1 receptors are also found in the substantial
nigra, as well as the caudate-putamen, nucleus accumbens, and olfactory
tubercle (Boyson et al., 1986). Ribonuclease protein assays and in-situ
hybridization suggest that D5 receptors are found in low numbers in the
hippocampus, cortex, substantia nigra, thalamus, nucleus accumbens and
caudate-putamen (Choi, Machida, & Ronnekleiv, 1995; Meador-Woodruff,
Mansour, Grandy, Damask, Civelli, & Watson, 1992).
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D2-Like Receptors
D2-like receptors, in contrast to D1-like receptors, function in an
inhibitory manner (Keeler, Pretsell, & Robbins, 2014). D2-like receptors are
coupled with Gi complexes that, when stimulated, inhibit the activation of
adenylyl cyclase (Kebabian, Beaulieu, & Itoh, 1984; Onali, Schwartz, & Costa,
1981). In contrast to D1-like receptors, D2-like receptors have a high affinity
for dopamine, and are more sensitive to changes in tonic dopamine release
(Dreyer et al., 2010; Kebabian et al., 1984).
D2 receptors are distributed widely throughout the brain, but are found
in lesser densities than D1 receptors (Boyson et al., 1986). Using
autoradiography, Boyson et al. (1986) found substantial numbers of D2
receptors in the caudate-putamen, nucleus accumbens, olfactory tubercle,
substantia nigra, and choroid plexus. In-situ hybridization studies support the
presence of D2 receptors in the nucleus accumbens, olfactory tubercle, and
substantia nigra, as well as the ventral tegmental area (Meador-Woodruff,
Mansour, Bunzow, Van Tol, Watson, & Civelli, 1989).
D3 receptors are not as widely distributed as D2 receptors. In a study
employing both autoradiography and in-situ hybridization, D3 receptors were
expressed abundantly in the islands of Calleja, but were expressed more
restrictedly in the nucleus accumbens, substantia nigra, ventral tegmental
area, and cerebellum (Diaz, Lévesque, Lammers, Griffon, Martres, Schwartz,
& Sokoloff, 1995). Finally, while D2 and D3 receptors are primarily expressed
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in the basal ganglia, D4 receptors are mainly found in the entorhinal cortex,
lateral septal nucleus, hippocampus, and the medial preoptic area of the
hypothalamus (Primus, Thurkauf, Xu, Yevich, McInerney, Shaw, Tallman, &
Gallager, 1997).

Ontogeny of the Dopamine System
It is well established that the dopamine system changes throughout
ontogeny. Interestingly, D1-like and D2-like receptors develop on different
schedules. Specifically, D1-like receptors are most abundant at postnatal day
(PD) 40, whereas, D2-like receptor numbers peak between PD 25 and 40
(Teicher, Andersen, & Hostetter, 1995). After these time points, the receptors
are pruned to adult levels (Teicher et al., 1995). In addition, the rate of
proliferation of D1-like and D2-like receptors varies across ontogeny.
Although rats are born with an approximately equal number of each receptor
type, there are three times as many D1-like receptors than D2-like receptors
when rats reach adulthood (Gelbard, Teicher, Faedda, & Baldessarini, 1989).
The concentration of dopamine in the central nervous system also
changes across early development. Specifically, dopamine levels in rat brain
increase steadily until adulthood (Agrawal, Glisson, & Himwich, 1966). In
addition, the daily cyclicity of brain dopamine levels differs according to age.
For example, radioenzymatic assays show that dopamine concentrations in 3and 21-day-old rabbits peak during the early light phase; whereas, the
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dopamine concentrations of adult animals peak during the early dark phase
(Gingras, Lawson, & McNamara, 1995). Further, different brainstem regions
develop unique patterns of dopamine cyclicity that change across ontogeny
(Gingras et al., 1995).
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CHAPTER THREE
SEROTONIN AND NOREPINEPHRINE PHARMACOLOGY

Introduction: Serotonin
The monoamine neurotransmitter 5-hydroxytryptamine (5-HT), more
commonly referred to as serotonin, is found diffusely across the central
nervous system. Serotonin has a role in many cognitive processes, such as
anxiety, memory, and aggression (Bear, Connors, & Paradiso, 2007). In
addition, serotonin modulates the release of many other neurotransmitters,
such as glutamate, GABA, epinephrine, norepinephrine, and dopamine
(Ciranna, 2006). The modulatory action of serotonin is also important for the
control of motor movement, as serotonin receptor antagonists attenuate
hyperlocomotion and stereotypy (Carlsson, Martin, Nilsson, Sorenson,
Carlsson, Waters, & Waters, 1999; Higgins, Enderlin, Haman, & Fletcher,
2003). Because of the varied roles of serotonin, it is no surprise that
serotonergic dysfunction is implicated in several diseases, such as major
depression, Alzheimer’s Disease, and schizophrenia (Ciranna, 2006).

Serotonin Synthesis
Serotonin is synthesized in the central nervous system in two steps.
First, tryptophan is hydroxylated by tryptophan hydroxylase (TPH) to form 5hydroxytryptophan (5-HTP). Second, 5-HTP is decarboxylated by aromatic L-
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amino acid decarboxylase (AADC) to create serotonin (Fitzpatrick, 1999; Li,
Chalazonitis, Huang, Mann, Margolis, Yang, Kim, Côté, Mallet, & Gershon,
2011). This process primarily occurs in the raphe, where the majority of
serotonergic cell bodies are located (Abrams, Johnson, Hollis, & Lowry,
2004).
The location of serotonergic cell clusters has largely been studied with
immunocytochemical localization, and can be grouped into three pathways
(Cooper, Bloom & Roth, 2003). The serotonergic cell bodies located more
caudally project to the medulla and spinal cord, whereas the cell bodies
located more rostrally project to the telencephalon and diencephalon. Finally,
the clusters located in intermediate areas primarily innervate the cortex
(Cooper et al., 2003).

Classification of Serotonin Receptors
Serotonin receptors are generally categorized into seven distinct
families. The families, 5-HT1-7, include subtypes that differ slightly in structure
and function (for reviews, see Barnes & Sharp, 1999; Bradley, Engel, Feniuk,
Fozard, Humphrey, Middlemiss, Mylecharane, Richardson, & Saxena, 1986;
Glennon, 2003; Hoyer, Hannon, & Martin, 2002; Tecott & Julius, 1993). With
the exception of 5-HT3, which is ligand gated, most of the serotonin receptor
types are coupled to G proteins (Ciranna, 2006). Typically, serotonin
receptors are studied using radioligand binding assays, autoradiographic
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mapping, and, more recently, in-situ hybridization (Hoyer et al., 2002). Using
in-situ hybridization, Sumner, Rosie, and Fink (1992) reported that 5-HT1a
mRNA was found in the suprachiasmatic nucleus, supraoptic nucleus,
paraventricular nucleus, medial septum, medial preoptic area, ventromedial
hypothalamic nucleus, and perikarya of the diagonal band of Broca, as well
as the hippocampus. Autoradiographic analysis revealed that 5-HT1a binding
sites were highly concentrated in the dentate gyrus, hippocampus, lateral
septum, and frontal cortex, whereas 5-HT1b binding sites were highly
concentrated in the caudate nucleus, globus pallidus, and substantia nigra
(Vergé, Daval, Marcinkiewicz, Patey, el Mestikawy, Gozian, & Hamon, 1986).
5-HT1c mRNA, on the other hand, was found in the dorsal and median raphe
nuclei, as well as the lateral septum and choroid plexus (Sumner et al., 1992).
Not surprisingly, in-situ hybridization and autoradiography have
revealed that 5-HT2 and 5-HT3 receptors are found in similar locations as the
5-HT1 family. For example, 5-HT2 mRNA was found in the cingulate and
frontal cortices, medial septum, medial preoptic area, ventromedial
hypothalamic nucleus, perikarya of the diagonal band of Broca, and dorsal
and median raphe nuclei (Sumner et al., 1992). In addition, autoradiographic
analysis revealed a high density of 5-HT2 receptor binding sites in the cortex
and the caudate putamen (Schotte & Leysen, 1988). Further, calcium binding
has shown that 5-HT3 mRNA is located in the neocortex, olfactory cortex,
hippocampus, and amygdala (Morales & Bloom, 1997). Using
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autoradiography, high densities of 5-HT3 receptor binding sites were also
found in the amygdala, hippocampus, frontal cortex, and entorhinal cortex
(Laporte, Koscielniak, Ponchant, Vergé, Hamon, & Gozlan, 1992).

Ontogeny of the Serotonin System
In rats, 5-HT neurotransmitter levels peak at PD 5, and then decline
until PD 7 (Artigas, Suñol, Tussel, Martínez, & Gelpí, 1985; Bennett &
Giarman, 1965; Nachmias, 1960). Following PD 7, 5-HT levels increase
gradually until they reach adult levels at about PD 15 (Artigas et al., 1985).
Importantly, the density of serotonergic receptors changes across ontogeny.
In rats, the density of 5-HT1 receptors increases after birth, with adult levels
being reached around PD 9 to PD 14 (Zilles, Schleicher, Glaser, Traber, &
Rath, 1985). In contrast, 5-HT2 receptor densities increase rapidly during the
first postnatal week, until asymptoting at PD 7 (Morilak & Ciaranello, 1993). At
PD 28, 5-HT2 receptor levels then decline to adult levels (Morilak &
Ciaranello, 1993).

Introduction: Norepinephrine
Norepinephrine, like dopamine, is a catecholamine neurotransmitter
that derives from tyrosine (Kujar et al., 1999). Norepinephrine was first
discovered in 1946 by Ulf von Euler, and further investigated by Peter Holtz in
1957 (Shore & Olin, 1958). In general, norepinephrine is important for the
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“fight or flight” response, but it is also critical for attention, cognition, learning,
memory, stress, and mood regulation (Aston-Jones, Rajkowski, & Cohen,
1999; Ordway, Schwartz & Frazer, 2012). Because norepinephrine is
necessary for many basic brain functions, it is not a surprise that dysfunction
involving this system can lead to disorders such as major depression, anxiety,
and schizophrenia (Anand & Charney, 2000; Biederman & Spencer, 1999;
Goldstein, 1981; Redmond & Huang, 1979).

Norepinephrine Synthesis
Norepinephrine is a catecholamine that derives from phenylalanine.
First, tyrosine hydroxylase converts tyrosine into L-DOPA. Second, L-DOPA
is catalyzed by aromatic amino acid decarboxylase, resulting in dopamine
(Roth, 1979; Sourkes, 1979). Finally, dopamine is transported into vesicles
where it is converted by the enzyme dopamine β-hydroxylase into
norepinephrine (Kaufman, 1974; Kujar et al., 1999). Cell bodies of
noradrenergic neurons are primarily located in the pons, especially in the
locus coeruleus (Samuels & Szabadi, 2008). From the locus coeruleus,
noradrenergic projections form two major pathways (Noback, Strominger,
Demarest, & Ruggiero, 2005). First, axons comprising the central tegmental
tract project to the hypothalamus (Nurcombe & Gallagher, 1986). Second, the
dorsal longitudinal fasciculus innervates the medulla, cortex, thalamus, and
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hippocampus (Nurcombe et al., 1986). Rostrally, these pathways converge in
the medial forebrain bundle (Segal, Yager, & Sullivan, 1976).

Classification of Norepinephrine Receptors
There are two families of adrenergic receptors, alpha and beta
(Ordway et al., 2012). Adrenergic receptors from both families are coupled to
G proteins (Qin, Sethi, & Lambert, 2008). The alpha family has two subtypes
(α1 and α2), and the beta family has three subtypes (β1, β2, and β3). Recently,
the α1 and α2 subtypes have each been further classified into three groups
(α1a, α1b, and α1d; α2a, α2b, and α2c) (Taniguchi, Ukai, Tanaka, Yano, Kimura,
Moriyama, & Kawabe, 1997). In-situ hybridization studies show that mRNA of
the α1a group was found mainly in the globus pallidus, olfactory bulb, and
spinal cord (Chapple, Burt, Andersson, Greengrass, Wyllie, & Marshall,
1994), whereas α1b and α1d mRNA is located mainly in the cortex (Weinberg,
Trivedi, Tan, Mitra, Perkins-Barrow, Borkowski, Strader, & Bayne, 1994). In
contrast, receptors from the α2 groups are more widely dispersed in the brain.
For example, in-situ hybridization studies show that α2a mRNA is located in
the cortex, locus coeruleus, reticular formation, pontine nuclei, thoracic spinal
cord, and the paraventricular nucleus of the hypothalamus (Dalman & Neubig,
1991; Nicholas, Pieribone, & Hökfelt, 1993). In the central nervous system, a
small amount of α2b-receptor mRNA is found in the hypothalamus; whereas,
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α2c-receptor mRNA is located in the olfactory bulb, cortex, striatum, dorsal
root ganglion, and hippocampus (Nicholas et al., 1993).
The second family of norepinephrine receptors, the β-adrenergic, has
three subtypes. The α1 subtype is not found in the central nervous system, but
rather in cardiac and stomach tissue (Zhao, Sakata, Li, Liang, Richardson,
Brown, Goldstein, & Zigman, 2010). This is also the case for the β3 subtype,
which is found in the colon, gall bladder, and adipose tissue (Krief, Lönnqvist,
Raimbault, Baude, Van Spronsen, Arner, Strosberg, Ricquier, & Emorine,
1993). In contrast, β2-receptors are located in the amygdala, cerebellum, and
cortex, as well as the heart, smooth muscle, liver, and kidneys (Beane &
Marrocco, 2004; Elenkov, Wilder, Chrousos, & Vizi, 2000).

Ontogeny of the Norepinephrine System
The levels of norepinephrine in the developing rat brain follow a similar
pattern as the levels of serotonin. Norepinephrine neurotransmitter levels
increase dramatically from PD 1 to PD 2 (Dygalo, Iushkova, Kalinina, Surnina,
Mel’nikova, & Shishkina, 2000). After the initial peak, there is a decline until
PD 5, after which there is a gradual increase until PD 30 when adult levels
are reached (Dygalo et al., 2000; Karki, Kuntzman, & Brodie, 1962).
In terms of receptor densities, β-adrenergic receptors sharply increase
in density soon after birth, and at three weeks achieve adult levels (Dygalo et
al., 2000). In contrast, adult-like levels of α2-receptors are already present at
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PD 1 (Happe, Coulter, Gerety, Sanders, O’Rourke, Bylund & Murrin, 2004).
Interestingly, the density of α1-receptors depends on neuroanatomical
location. For example, α1-receptors in the globus pallidus increase in density
from PD 1 to PD 7, and then undergo pruning throughout the remainder of
life. In the olfactory bulb, α1-receptors increase in number for the first two
weeks after birth and then remain at a constant level thereafter (Jones,
Gauger, Davis, Slotkin & Bartolome, 1985).
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CHAPTER FOUR
ADULT BEHAVIORAL SENSITIZATION

Indirect Dopamine Agonists: Adult Multi-Trial
Behavioral Sensitization
Typically, multi-trial behavioral sensitization consists of 4-6 daily
injections of an indirect dopamine agonist, followed by a withdrawal period,
and then the administration of a challenge injection of the same agonist
(Robinson & Becker, 1986). Sensitization is characterized by a heightened
behavioral response following the challenge injection. Enhanced locomotor
activity is the most commonly studied sensitized response in rats, although
intense stereotypy can also occur. A multiphasic behavioral response is also
possible. For example, repeatedly administering a high dose of amphetamine
causes an initial increase in locomotor activity followed by intense stereotypy,
and then a period of post-stereotypy locomotion (Leith & Kuczenski, 1982).
These components of the sensitized response persist for different periods of
time, with stereotypy lasting longer than locomotor activity (Leith & Kuczenski,
1982).
Although the persistance of sensitized stereotypy and locomotor
activity differ, the intensity of each response is similarly affected by drug dose.
Specifically, larger doses of a psychostimulant will produce more robust
sensitized stereotypy and locomotor activity (Frantz, O’Dell, & Parsons, 2007;
Post & Rose, 1976). For example, five administrations of a small dose (10
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mg/kg) of cocaine lead to increased locomotion and stereotypy, whereas six
administrations of a large dose (40 mg/kg) of cocaine generated more intense
locomotion and stereotypy (Davidson, Lazarus, Lee, & Ellinwood, 2002;
Frantz et al., 2007). Even at smaller doses of amphetamine (0.5, 1.0, or 1.5
mg/kg), a gradual strengthening of the sensitized response occurs as the
drug dose increases (Hooks, Jones, Neill, & Justice, 1992). In sum, it is clear
that in multi-trial behavioral sensitization the psychostimulant dose is
positively correlated with the intensity of the sensitized response.
Importantly, the multi-trial procedure produces a sensitized locomotor
response that persists for a long period of time in adult rats. In fact, behavioral
sensitization can be observed for many months after drug administration is
discontinued (Kalivas & Stewart, 1991; Kolta et al., 1985; Leith & Kuczenski,
1982; Robinson & Becker, 1986). In general, the robustness of the sensitized
response to cocaine and amphetamine increases as the period of withdrawal
increases (Heidbreder, Thompson, & Shippenberg, 1996; Kalivas & Duffy,
1993a, 1993b; Kolta et al., 1985; Segal & Kuczenski, 1992; Vanderschuren,
Schmidt, De Vries, Van Moorsel, Tilders, & Schoffelmeer, 1999). Behavioral
sensitization observed within a week of drug discontinuation is considered
short-term sensitization, whereas a sensitized response observed weeks to
months later is considered long-term sensitization. This distinction is
important, since the neural mechanisms mediating short- and long-term
behavioral sensitization differ. In fact, the neuroadaptations responsible for
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short-term behavioral sensitization disappear over time, yet are a necessary
precursor for neuroadaptations that support long-term sensitization (for
reviews, see Pierce & Kalivas, 1997; White, Hu, Zhang, & Wolf, 1995; White
& Kalivas, 1998; Wolf, 1998).
The robustness of the sensitized response can also be affected by the
context in which the drug is administered. It is evident that a stronger
sensitized response occurs when drug pretreatment and testing occur in the
same environment (Anagnostaras & Robinson, 1996). Context independent
sensitization is possible, but only when higher doses of cocaine are
repeatedly administered to adult rats or mice (Badiani, Browman, & Robinson,
1995; Browman, Badiani, & Robinson, 1998; Crombag, Badiani, Chan,
Dell’Orco, Dineen, & Robinson, 2001). Similarly, multi-trial amphetamine
sensitization is more robust when the drug is administered in a previously
novel environment (Crombag, Badiani, Maren, & Robinson, 2000). In addition,
drug-environment associations are important for the persistence of the
sensitized response (Anagnostaras & Robinson, 1996). Together, these
results show that associative learning is an important part of the sensitization
process in adult rats and mice.
Pavlovian conditioning is the primary associative process involved in
behavioral sensitization. Specifically, the environmental context acts as the
conditioned stimulus (CS), and the psychostimulant is the unconditioned
stimulus (US). After repeated drug-environment pairings, the CS elicits a
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potentiated locomotor response (i.e., a conditioned response, CR) if the
animal is tested in the same environmental context (Franklin & Druhan, 2000;
Johnson, Sediqzadah, & Erb, 2012; Michel & Tirelli, 2002). According to
classical learning theory, the robustness of the CR should increase with the
number of CS-US pairings (Mackintosh, 1974). Consistent with this tenet,
Michel, Tambour, and Tirelli (2003) found that rats injected with cocaine for
12 days, as opposed to 3 or 6 days, exhibited a more robust sensitized
response on the test day. As will be discussed shortly, Pavlovian contextual
conditioning appears to be even more essential for the one-trial behavioral
sensitization of adult rats and mice (Battisti, Chang, Uretsky, & Wallace,
1999; Jackson & Nutt, 1993; Weiss et al., 1989).

Indirect Dopamine Agonists: Adult One-Trial
Behavioral Sensitization
Research regarding multi-trial behavioral sensitization in adults is
extensive; however, studies examining one-trial behavioral sensitization are
more limited. One-trial behavioral sensitization consists of two administrations
of the same drug (i.e., a pretreatment dose and a challenge dose). This
procedure is also known as a two-injection protocol of sensitization (TIPS;
Valjent et al., 2010). Relative to the multi-trial procedure, the one-trial
paradigm has some distinct advantages because it minimizes the possibility
of dopamine receptor up-regulation and dopamine supersensitivity due to
multiple agonist administrations (Mohd-Yusof et al., 2016; Robinson &
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Becker, 1986; Valjent et al., 2010; White, Joshi, Koeltzow, & Hu, 1998). The
one-trial paradigm also provides an unbiased procedure for differentiating the
induction and expression of behavioral sensitization (Valjent et al., 2010).
As with multi-trial behavioral sensitization, the one-trial procedure can
result in a sensitized locomotor or stereotypic response. With high doses of
amphetamine, intense stereotyped behaviors occur after a single conditioning
trial (Battisti et al., 1999). In contrast, locomotor sensitization is evident when
adult mice are pretreated with a single moderate dose of cocaine or morphine
(Valjent et al., 2010). The one-trial behavioral sensitization of adult rats and
mice shows great persistence, as a sensitized locomotor response is still
detectable months after a single psychostimulant administration (Fontana et
al., 1993; Robinson, Becker, & Presty, 1982; Valjent et al., 2010).
Although there is only one conditioning trial, associative learning is
necessary for the induction of one-trial behavioral sensitization in adult
animals (for a discussion, see White et al., 1998). While the induction of multitrial behavioral sensitization is strengthened by contextual conditioning, the
one-trial behavioral sensitization of adult rats and mice is completely context
dependent (Battisti et al., 1999; Jackson & Nutt, 1993; Weiss et al., 1989).
Several different methodologies have been employed to investigate whether
context-independent one-trial sensitization is obtainable, but all attempts thus
far have failed (Battisti et al., 1999; Weiss et al., 1989). For example, Battisti
et al. (1999) administered amphetamine or apomorphine to adult mice and
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then placed them in various environments (cages of different size, color, etc.).
When mice were tested in a distinctly different environment, there was no
evidence of a sensitized response. Context dependency can also be shown
when rats are pretreated with a psychostimulant in their home cage and then
tested in a novel environment (Badiani et al., 1995; Post, Lockfeld, Squillace,
& Contel, 1981). In addition, drug dose is an important constraint for one-trial
behavioral sensitization, because increasing the dose of the agonist
increases the intensity of the sensitized response (Battisti et al., 1999). This
finding is consistent with Pavlovian principles, as enhancing CS intensity (i.e.
the drug dose) should increase the robustness of the CR (i.e. the locomotor
response).
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CHAPTER FIVE
ADULT BEHAVIORAL SENSITIZATION:
NEURAL MECHANISMS

Studies regarding the neural mechanisms underlying multi-trial
behavioral sensitization in adult rats primarily focus on dopaminergic systems,
although recent studies have also examined serotonergic and noradrenergic
mediation. Interestingly, the neural mechanisms underlying behavioral
sensitization differ depending on the type of psychostimulant used. For
example, glutamatergic mechanisms involved in cocaine sensitization appear
to be unimportant for amphetamine sensitization (for a review, see
Vanderschuren & Kalivas, 2000).

Dopamine Receptor Systems Underlying
Behavioral Sensitization
Multi-Trial Behavioral Sensitization
Perhaps not surprisingly, the dopamine receptor subtypes mediating
the induction and expression of behavioral sensitization differ according to
both the induction paradigm employed (one- vs. multi-trial) and the
psychostimulant used. For example, neither D1-like nor D2-like receptor
antagonists block the induction of multi-trial cocaine sensitization in adult rats
(Mattingly, Hart, Lim & Perkins, 1994). In contrast, both D1-like and D2-like
receptor antagonists block the induction of multi-trial amphetamine and

27

methamphetamine sensitization (Kelly, Low, Rubinstein & Phillips, 2008;
Kuribara & Uchihashi, 1993, 1994; White et al., 1998). Dopamine receptors
play a different role in the expression of multi-trial behavioral sensitization.
More specifically, the expression of multi-trial cocaine sensitization is
prevented when D1-like receptor antagonists are administered before cocaine
on the test day (Sorg, Li, & Wu, 2001; White et al., 1998). In contrast, D1-like
and D2-like receptor antagonists do not block the expression of
amphetamine-induced multi-trial behavioral sensitization in adult rats (Moro,
Sato, Ida, Oshima, Sakurai, Shihara, Horikawa, & Mukini, 2007).
One-Trial Behavioral Sensitization
Unlike multi-trial behavioral sensitization, a functioning dopamine
system is necessary for the induction of one-trial cocaine sensitization in adult
rats. It has been reported in more than one study that D1-like and D2-like
receptor antagonists block the induction of one-trial cocaine sensitization in
adult rats (Fontana et al., 1993; Weiss et al., 1989; see also Valjent et al.,
2010). Interestingly, expression of one-trial cocaine sensitization is not
affected by dopamine receptor antagonism, since administering D1-like and
D2-like receptor antagonists before cocaine treatment on the test day does
not prevent the occurrence of a sensitized response (Fontana et al., 1993).
No studies have examined the effects of selective dopamine receptor
antagonists on the induction and expression of one-trial amphetamine and
methamphetamine behavioral sensitization.
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In summary, a number of interesting yet inconsistent findings have
been reported concerning cocaine sensitization: first, neither D1-like nor D2like receptor antagonists block the induction of multi-trial behavioral
sensitization; second, both D1-like and D2-like receptor antagonists block the
induction of one-trial behavioral sensitization; third, only D1-like receptor
antagonists block the expression of multi-trial behavioral sensitization; and
fourth, neither D1-like nor D2-like receptor antagonists block the expression
of one-trial behavioral sensitization.

Serotonin and Adrenergic Receptor Systems
Underlying Behavioral Sensitization
The inconsistent actions of D1-like and D2-like receptor antagonists on
the induction and expression of cocaine sensitization strongly suggest that
some other receptor system is more fundamentally involved in mediating the
neural processes underlying behavioral sensitization. Because cocaine
increases synaptic levels of both dopamine and serotonin (for reviews, see
Meyer & Quenzer, 2005; Vanderschuren & Kalivas, 2000), White et al. (1998)
proposed that redundant dopamine and serotonin pathways may mediate the
induction of cocaine sensitization. In fact, recent evidence suggests that the
serotonergic system, as well as the noradrenergic system, are important
mediators of behavioral sensitization.
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Serotonin Receptor Systems: Multi-Trial Behavioral Sensitization
In terms of the serotonin system, the involvement of specific receptor
subtypes in behavioral sensitization appears to depend on the
psychostimulant used. For example, 5-HT2C receptor antagonists block the
induction of multi-trial cocaine sensitization (Craige & Unterwald, 2013);
whereas, the induction of multi-trial methamphetamine sensitization is
blocked by a 5-HT3 receptor antagonist (Yoo, Nam, Lee, & Jang, 2006). The
serotonergic receptors mediating the induction of multi-trial behavioral
sensitization are often the same as those mediating expression. For instance,
5-HT2 and 5-HT3 receptor antagonists block the expression of multi-trial
cocaine sensitization in adult rats (Davidson, Lazarus, Xiong, Lee, &
Ellinwood, 2002; King, Xiong, Douglas, & Ellinwood, 2000; King, Xiong, &
Ellinwood, 1998). In addition, the expression of methamphetamine-induced
multi-trial behavioral sensitization is prevented by the non-selective 5-HT2
receptor antagonist ritanserin (Ago, Nakamura, Baba, & Matsuda, 2007).
Serotonin Receptor Systems: One-Trial Behavioral Sensitization
The serotonergic receptors necessary for multi-trial behavioral
sensitization are also important for one-trial sensitization. For example,
administering 5-HT3, 5-HT2A, and 5-HT2C receptor antagonists prior to
methamphetamine on the pretreatment day blocks the induction of one-trial
behavioral sensitization (Steed, Jones, & McCreary, 2011; Yoo, Nam, Lee, &
Jang, 2008). The induction of amphetamine and cocaine one-trial behavioral
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sensitization is also prevented by 5-HT2 receptor antagonism (O’Neill, HeronMaxwell, & Shaw, 1999). Unfortunately, no studies have examined the effects
of selective serotonin antagonists on the expression of one-trial cocaine and
methamphetamine sensitization. In summary, it is clear that the 5-HT2 and 5HT3 receptor families are important for the induction of multi- and one-trial
behavioral sensitization of adult animals, but their role in expression is
uncertain.
Adrenergic Receptor Systems: Multi-Trial Behavioral Sensitization
Studies examining the role of adrenergic receptor systems in
behavioral sensitization are less abundant than those assessing serotonin
and dopamine system involvement. In a comprehensive study, Auclair et al.
(2004) found that concomitant administration of 5-HT2 and α1-adrenergic
receptor antagonists inhibits the induction and expression of multi-trial
behavioral sensitization to both amphetamine and cocaine (Auclair et al.,
2004; see also Drouin, Blanc, Villégier, Glowinski, & Tassin, 2002).
Consistent with these findings, amphetamine- and cocaine-induced locomotor
activity is dramatically attenuated in mice lacking α1-adrenergic receptors
(Drouin et al., 2002). The locus of these effects may be the nucleus
accumbens, since infusing an α1-adrenergic antagonist into the accumbens
prevents the induction of amphetamine-induced behavioral sensitization
(Blanc, Trovero, Vezina, Hervé, Godeheu, Glowinski, & Tassin, 1994).
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Adrenergic Receptor Systems: One-Trial Behavioral Sensitization
Studies investigating the involvement of the adrenergic receptor
system in one-trial behavioral sensitization are limited. Both α2-adrenergic
and α1-adrenergic antagonists block the induction of amphetamine
sensitization, but not cocaine sensitization (Vanderschuren, Beemster, &
Schoffelmeer, 2003). As mentioned above, concurrent blockade of 5-HT2 and
α1-adrenergic receptors prevents the induction of one-trial cocaine and
amphetamine sensitization (Auclair et al., 2004). No studies have examined
the effects of selective adrenergic antagonists on the expression of one-trial
behavioral sensitization in adult rats.
In summary, receptor antagonist and knock-out studies provide strong
evidence that serotonin and norepinephrine receptor systems mediate at least
some components of behavioral sensitization. First, 5-HT2 receptor
antagonists block the induction of one- and multi-trial cocaine sensitization;
second, 5-HT3 receptor antagonists prevent the induction of one-trial
methamphetamine sensitization; third, co-administration of 5-HT2 and α1adrenergic receptor antagonists completely prevents the induction and
expression of cocaine and methamphetamine multi-trial sensitization; and,
fourth, “knocking out” α1-adrenergic receptors attenuates psychostimulantinduced locomotor activity. Collectively, the available evidence suggests that
the serotonergic and noradrenergic systems are critically involved in the
mediation of behavioral sensitization in adult rats and mice.
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CHAPTER SIX
PREWEANLING BEHAVIORAL SENSITIZATION

Indirect Dopamine Agonists: Preweanling
Multi-Trial Behavioral Sensitization
As is true of adult rats, psychostimulant-induced behavioral
sensitization occurs in young rats (Duke et al., 1997; McDougall et al., 1994;
Wood et al., 1998). Importantly, the manifestation of behavioral sensitization
is different in young rats, as the sensitized response in younger animals is
much less robust than in adults (Smith & Morrell, 2008). Additionally, the
sensitization of adult rats persists for months after cessation of drug
administration (Kalivas & Stewart, 1991; Leith & Kuczenski, 1982; Robinson &
Becker, 1986); whereas, the sensitized response of young rats only lasts for a
week or two after cessation of drug administration (McDougall et al., 1994;
Wood et al., 1998; Zavala et al., 2000). The latter finding suggests that the
neural mechanisms involved in long-term behavioral sensitization are not yet
mature in young rats. As for short-term behavioral sensitization, the
mechanisms underlying induction and expression are functional by at least
PD 10 (Tirelli, 2001).
As with adult rats, associative learning modifies the multi-trial
behavioral sensitization of preweanling rats. For example, repeatedly
administering cocaine in a novel environment causes a sensitized stereotypic
response in young rats; whereas, administering the drug in the home cage
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produces no sensitization (Wood et al., 1998). After 10 daily injections of
cocaine and a short abstinence period (i.e. one day) context-independent
behavioral sensitization occurs, although after a long abstinence period (i.e.
one week) behavioral sensitization is context-dependent (Zavala et al., 2000).
In addition, after only three pretreatment injections of cocaine and a 24 h
withdrawal period, context-independent behavioral sensitization occurs in
preweanling rats (McDougall et al., 2009). In agreement with classical
learning theory, the longevity of the sensitized response increases as the
number of pretreatment psychostimulant administrations increases (Zavala et
al., 2000). In other words, increasing the number of CS-US pairings enhances
the persistence of the CR.

Indirect Dopamine Agonists: Preweanling
One-Trial Behavioral Sensitization
Preweanling rats show robust one-trial psychostimulant-induced
behavioral sensitization (McDougall et al., 2007; McDougall, Kozanian,
Greenfield, Horn, Gutierrez, Mohd-Yusof, & Castellanos, 2011). The
sensitized response is strongest when testing occurs one to three days after
drug pretreatment and disappears entirely after five days (McDougall et al.,
2009). Interestingly, the different classes of dopamine agonists preferentially
induce behavioral sensitization at different ontogenetic ages (Kozanian,
Gutierrez, Mohd-Yusof, & McDougall, 2012; McDougall, Nuqui, Quiroz, &
Martinez, 2013; McDougall et al., 2011). For example, one-trial amphetamine-
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and methamphetamine-induced behavioral sensitization was observed in rats
tested on postnatal day (PD) 13 and PD 17 (McDougall et al., 2011, 2013);
whereas, cocaine preferentially induces behavioral sensitization at PD 21
(Kozanian et al., 2012). These data suggest that each drug activates the
neural mechanisms underlying behavioral sensitization in slightly different
ways.
Interestingly, the relative importance of contextual stimuli is the most
striking age-dependent difference in the ontogeny of behavioral sensitization.
In adult rats, contextual conditioning is necessary for robust one-trial
behavioral sensitization (Battisti, Uretsky, & Wallace, 2000; Jackson & Nutt,
1993; Weiss et al., 1989). In contrast, preweanling rats show strong contextindependent behavioral sensitization with the one-trial paradigm (Herbert,
Der-Ghazarian, Palmer, & McDougall, 2010; McDougall et al., 2009). For
example, preweanling rats pretreated with cocaine in the home cage or in a
novel chamber show no difference in sensitized responding when tested in an
activity chamber (Herbert et al., 2010). Furthermore, young rats anesthetized
before receiving a pretreatment injection of cocaine still show a sensitized
response on the test day (Herbert et al., 2010). Finally, electroconvulsive
shock-induced retrograde amnesia administered a few h after a pretreatment
dose of cocaine does not prevent the expression of a sensitized response
(McDougall et al., 2011). These various results show that associative learning
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processes are not necessary for the one-trial behavioral sensitization of
preweanling rats.
Overall, it is clear that behavioral sensitization is manifested differently
in preweanling and adult rats. Adult behavioral sensitization is more robust
than in preweanling rats (Smith & Morrell, 2008). In addition, the effects of
contextual conditioning are stronger in adults than pups, an effect that is
especially evident in the one-trial paradigm (Battisti et al., 2000; Herbert et al.,
2010; Jackson & Nutt, 1993; McDougall et al., 2009; Weiss et al., 1989).
Finally, the behavioral sensitization exhibited by adult rats shows much
greater persistence than in younger rats (Kalivas & Stewart, 1991; Kolta et al.,
1985; Leith & Kuczenski, 1982; Robinson & Becker, 1986; Zavala et al.,
2000). Taken together, the implications of these data are two-fold. First, the
neural mechanisms underlying behavioral sensitization appear to differ in
preweanling and adult rats. For example, young rats possess the nonassociative neural mechanisms necessary for short-term behavioral
sensitization, but evidence suggests that the processes mediating long-term
behavioral sensitization are not functional. Second, associative processes
may be necessary for robust long-term behavioral sensitization. Thus, the
associative deficits exhibited by preweanling rats may be the critical factor
responsible for both the weaker sensitized response and the striking lack of
persistence.
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CHAPTER SEVEN
PREWEANLING BEHAVIORAL SENSITIZATION:
NEURAL MECHANISMS

In contrast to studies using adult rats and mice, there are relatively few
studies examining the neural mechanisms mediating behavioral sensitization
in preweanling rats. According to the few existing ontogenetic studies, it
appears that the neural mechanisms governing the behavioral sensitization of
preweanling rats may differ depending on the induction paradigm employed
(one- vs. multi-trial).

Dopamine Receptor Systems Underlying
Behavioral Sensitization
Multi-Trial Behavioral Sensitization
Although few studies have assessed dopaminergic involvement in the
induction of multi-trial methamphetamine sensitization, none have examined
the role of dopamine receptors in the expression of multi-trial
methamphetamine sensitization. In terms of induction, administering a D2-like
receptor antagonist during the pretreatment phase attenuates the multi-trial
methamphetamine-induced behavioral sensitization of preweanling rats
(Mohd-Yusof et al., 2016). Interestingly, concurrent pretreatment with both
D1-like and D2-like receptor antagonists completely blocks the induction of
multi-trial methamphetamine sensitization (Mohd-Yusof et al., 2016). In other
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words, antagonizing both dopaminergic receptor types produces a greater
effect on the sensitized behavioral response than antagonizing the D2 system
alone. Unfortunately, there are no studies examining the induction or
expression of multi-trial cocaine sensitization during the preweanling period.
One-Trial Behavioral Sensitization
As mentioned above, the neural mechanisms underlying behavioral
sensitization appear to differ depending on the paradigm used (one- vs. multitrial). For example, Mohd-Yusof et al. (2014) reported that D1-like receptor
antagonism does not affect the induction of one-trial cocaine- or
methamphetamine-induced behavioral sensitization in young rats. Likewise,
D2-like receptor antagonism does not prevent the induction of one-trial
methamphetamine-induced behavioral sensitization (Mohd-Yusof et al.,
2016). In contrast to the multi-trial paradigm, concurrent D1-like and D2-like
receptor antagonism does not block the induction of one-trial
methamphetamine sensitization (Mohd-Yusof et al., 2016).
Although little is known concerning the neural mechanisms underlying
the expression of one-trial methamphetamine-induced behavioral
sensitization, there is a limited amount of information about the expression of
cocaine sensitization. Specifically, D1-like, but not D2-like, receptor
antagonists attenuate the expression of cocaine-induced one-trial behavioral
sensitization (McDougall, Rudberg, Veliz, Romero, Mohd-Yusof & Gonzalez,
2016). Administering a combination of D1-like and D2-like receptor

38

antagonists on the test day causes a decline in the locomotor activity of
preweanling rats, but it is uncertain whether this effect is due to the disruption
of the sensitization process or a general motoric disturbance (McDougall et
al., 2016). No studies have examined the expression of one-trial
methamphetamine-induced behavioral sensitization. Overall, there is an
unfortunate paucity of studies examining the involvement of the dopaminergic
system in one- and multi-trial behavioral sensitization.

Serotonin and Adrenergic Receptor Systems
Currently, there are no published studies that have examined whether
serotonergic and adrenergic receptor systems mediate the induction and
expression of behavioral sensitization during the preweanling period. The lack
of such studies leaves an important void in our understanding of the ontogeny
of behavioral sensitization.
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CHAPTER EIGHT
EEDQ

The drug N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) is a
nonselective irreversible receptor antagonist (Meller, Goldstein, Friedhoff, &
Schweitzer, 1988). Evidence suggests that EEDQ affects dopaminergic,
serotonergic, and adrenergic receptors. First, Belleau, Martel, Lacasse,
Ménard, Weinberg, and Perron (1968) discovered that EEDQ was an
irreversible α-adrenergic receptor antagonist in smooth muscle. Later, Kalsner
(1973) found that EEDQ was also effective in inactivating serotonergic
receptors in rabbit aortic tissue. Finally, Hamblin and Creese (1983) reported
that EEDQ was a potent and irreversible dopamine receptor antagonist.
More recently, studies have primarily focused on the effects of EEDQ
in the central nervous system. For instance, homogenate binding studies
revealed that 7.5 mg/kg EEDQ causes a 61-86% reduction in D1 and D2
receptor densities in the caudate-putamen of adult rats (Crawford, McDougall,
Rowlett, & Bardo, 1992). Importantly, Meller Bohmaker, Goldstein and
Friedhoff (1985) reported that dopaminergic receptors can be protected from
inactivation by injecting rats with selective dopamine receptor antagonists
prior to EEDQ administration. In addition to its dopaminergic actions, EEDQ
reduces 5-HT1A, 5-HT1B, 5-HT2, 5-HT1C, α2-adrenergic, GABA, and muscarinic
receptor densities in various brain regions of rats (Adler, Meller, & Goldstein,
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1985; Alper & Nelson, 2000; Miller, Lumpkin, Galpern, Greenblatt, & Shader,
1991; Norman, Eubanks, & Creese, 1989; Pinto & Battaglia, 1993).
EEDQ can also be useful for investigating the neural mechanisms
underlying behavior. For example, systemic or bilateral administration of
EEDQ attenuates the dopamine agonist-induced locomotor activity of adult
rats (Der-Ghazarian, Gutierrez, Varela, Herbert, Amodeo, Charntikov,
Crawford, & McDougall, 2012; McDougall, Crawford, & Nonneman, 1992);
whereas, unilateral administration of EEDQ in the caudate-putamen causes
ipsilateral circling (Giorgi & Biggio, 1990a, 1990b). Additionally, EEDQ
attenuates or completely blocks apomorphine- and NPA-induced stereotypy
(Cameron & Crocker, 1989; Meller, Bordi, & Bohmaker, 1989). Therefore, it is
clear that EEDQ-induced receptor inactivation attenuates the dopaminemediated behaviors of adult rats.
Because EEDQ is a nonselective irreversible antagonist, additional
techniques are required to specify which receptor types mediate particular
behaviors. As mentioned above, it is possible to protect one or more receptor
types from the effects of EEDQ, thus allowing the actions of these receptors
to be individually studied. For example, selectively inactivating D2-like
receptors, but not D1-like receptors, inhibits apomorphine-induced stereotypy
(Arnt, Hyttel, & Meier, 1988; Cameron & Crocker, 1988). Additionally, Arnt
and Hyttel (1989) reported that selectively inactivating D1-like or D2-like
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receptors in the caudate-putamen of adult rats attenuates the circling
behavior produced by selective dopamine agonists.
Ineterestingly, few EEDQ studies have focused on learned behaviors,
as opposed to unlearned behaviors (Arnt et al., 1988; Arnt & Hyttel, 1989;
Der-Ghazarian, Widarma, Gutierrez, Amodeo, Valentine, Humphrey,
Gonzalez, Crawford, & McDougall, 2014). Although, McDougall et al. (2016)
have used EEDQ as a tool to assess whether D1-like and/or D2-like receptors
mediate behavioral sensitization in preweanling rats. Based on the results of
this study, it was reported that neither D1-like nor D2-like receptors mediate
the induction of cocaine sensitization during the preweanling period.
Unfortunately, the same study did not shed light on which receptor systems
do mediate the induction of cocaine sensitization in preweanling rats
(McDougall et al., 2016).
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CHAPTER NINE
SUMMARY AND THESIS STATEMENT

Behavioral sensitization is an important component of the addiction
process (Robinson & Berridge, 1993). Several factors, such as age, induction
paradigm (one- vs. multi-trial), and environmental context, influence the
manifestation of behavioral sensitization. In terms of age, the behavioral
sensitization of preweanling rats is less robust and persists for a much shorter
period of time than it does in adults (Smith & Morrell, 2008; Tirelli et al., 2003).
The neural mechanisms underlying behavioral sensitization also differ
depending on the psychostimulant used, the induction paradigm and, perhaps,
age. For example, D1-like and D2-like receptor antagonists prevent the induction
of one-trial cocaine-induced behavioral sensitization during adulthood (Fontana
et al., 1993; Weiss et al., 1989), but not during the preweanling period (MohdYusof et al., 2014). The latter result suggests that some other receptor type
mediates the induction of behavioral sensitization in preweanling rats.
Suggestively, Auclair et al. (2004) reported that serotonin and adrenergic
receptor antagonists inhibit the induction and expression of behavioral
sensitization in adult mice. Unfortunately, no studies have examined the
importance of serotonergic and adrenergic systems for the induction or
expression of behavioral sensitization during the preweanling period.
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The purpose of this thesis was to assess the involvement of the
serotonergic and adrenergic systems in the induction and expression of one-trial
cocaine-induced behavioral sensitization. Rats were assessed during the late
preweanling period (PD 18-21), when cocaine sensitization is most robust
(Kozanian et al., 2012). The aims of this thesis were two-fold: first, to determine
whether EEDQ prevents the induction or expression of one-trial cocaine
sensitization. It was hypothesized that EEDQ would prevent both the induction
and expression of one-trial cocaine sensitization. This hypothesis was based on
combined evidence that the dopaminergic, serotonergic, and adrenergic receptor
systems mediate behavioral sensitization.
The second goal of this thesis was to differentiate among the receptor
types and determine whether 5-HT and/or 𝛼1-adrenergic receptors mediate the
induction and/or expression of cocaine sensitization during the preweanling
period. It was hypothesized that both 5-HT and 𝛼1-adrenergic receptor
stimulation will be necessary for the induction and expression of behavioral
sensitization. This hypothesis was based on evidence from the adult mouse
literature showing that each of these receptor types is involved in the induction
and expression of multi-trial psychostimulant-induced behavioral sensitization
(Auclair et al., 2004).
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CHAPTER TEN
MATERIALS AND METHODS

Subjects
Subjects were 320 (n=8 per group) young male and female rats of
Sprague–Dawley descent (Charles River, Hollister, CA) that were born and
raised at California State University, San Bernardino (CSUSB). Litters were
culled to ten pups on PD 3. Rats were housed in large polycarbonate maternity
cages (30.5 × 43 × 19 cm) on a ventilated rack. Food and water was freely
available. The colony room was maintained at 22–23 °C and kept under a 12:12
light/dark cycle. Except during testing, rats were kept with the dam and
littermates. Testing was done in a separate experimental room and was
conducted during the light phase of the cycle. Subjects were cared for according
to the “Guide for the Care and Use of Laboratory Animals” (National Research
Council, 2010) under a research protocol approved by the Institutional Animal
Care and Use Committee of CSUSB.

Apparatus
Behavioral testing was done in activity monitoring chambers (25.5 × 25.5
× 41 cm) that consist of acrylic walls, a plastic floor, and an open top (Coulbourn
Instruments, Whitehall, PA). Each chamber includes an X–Y photobeam array,

45

with 16 photocells and detectors, that was used to determine distance traveled (a
measure of locomotor activity).

Drugs
EEDQ was dissolved in a 50% DMSO solution (1:1 (v/v) in distilled water),
while (-)-cocaine hydrochloride and prazosin hydrochloride were dissolved in
saline. Ritanserin was dissolved in a minimal amount of glacial acetic acid (15
µl/ml) and diluted in saline. All drugs were purchased from Sigma-Aldrich (St.
Louis, MO) and injected intraperitoneally (IP) at a volume of 5 ml/kg.

Procedure
Experiment 1: Effects of EEDQ on the Induction of One-Trial
Cocaine-Induced Behavioral Sensitization
On the preinjection day (PD 18), rats were injected with EEDQ (0, 7.5, or
15 mg/kg) and immediately returned to their home cage. On the pretreatment
day, which occurred 24 h later (PD 19), half of the rats in each group were
injected with saline and the other half received 30 mg/kg cocaine. Immediately
afterwards, rats were placed in activity chambers for 30 min and distance
traveled was recorded. On the test day (PD 21), all rats (n=8 per group) were
injected with 20 mg/kg cocaine and placed in activity chambers for 120 min. The
design of Experiment 1 is shown in Table 1.
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Experiment 2a: The Use of 5-HT and/or α1-Adrenergic Receptor
Protection to Assess the Effects of EEDQ on the Induction of
One-Trial Cocaine-Induced Behavioral Sensitization
On the preinjection day (PD 18), rats first received a protection injection of
prazosin (25 mg/kg), ritanserin (3 mg/kg), prazosin+ritanserin, or saline in the
home cage. After 30 min, rats received a preinjection of EEDQ (15 mg/kg). A
separate control group received a protection injection of saline and a preinjection
of vehicle. On the pretreatment day, which occurred 24 h later (PD 19), half of
the rats in each group received saline and the other half received 30 mg/kg
cocaine. Immediately afterwards, rats were placed in activity chambers for 30
min and distance traveled was recorded.
Table 1. Design of Experiment 1
Group

Treatment (Age)
Preinjection

Pretreatment Day

Test Day

(PD 18)

(PD 19)

(PD 21)

Acute Control Group

Vehicle

Saline

Cocaine

Sensitization Control
Group

Vehicle

Cocaine

Cocaine

7.5 mg/kg EEDQ Acute
Control

7.5 mg/kg EEDQ

Saline

Cocaine

7.5 mg/kg EEDQ
Sensitization

7.5 mg/kg EEDQ

Cocaine

Cocaine

15 mg/kg EEDQ Acute
Control

15 mg/kg EEDQ

Saline

Cocaine

15 mg/kg EEDQ
Sensitization

15 mg/kg EEDQ

Cocaine

Cocaine
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On the test day (PD 21), all rats (n=8 per group) were injected with 20 mg/kg
cocaine and placed in activity chambers for 120 min. The design of Experiment
2a is shown in Table 2.
Experiment 2b: Effects of Ritanserin and Prazosin on the Induction
of One-Trial Cocaine Sensitization
A separate four group experiment was conducted to determine whether
the protection treatments affected the locomotor activity of nonEEDQ-treated
rats. On the preinjection day (PD 18), rats first received an injection of saline or
prazosin+ritanserin in the home cage. After 30 min, all rats received a
preinjection of vehicle. On the pretreatment day, which occurred 24 h later (PD
19), half of the rats in each group received saline and the other half received 30
mg/kg cocaine. Immediately afterwards, rats were placed in activity chambers for
30 min and distance traveled was recorded. On the test day (PD 21), all rats (n=6
per group) were injected with 20 mg/kg cocaine and placed in activity chambers
for 120 min. The design of Experiment 2b is shown in Table 3.
Experiment 3: Effects of EEDQ on the Expression of One-Trial
Cocaine-Induced Behavioral Sensitization
On the pretreatment day (PD 19), rats were injected with saline or 30
mg/kg cocaine and placed in activity chambers for 30 min. On the preinjection
day, which occurred 24 h later (PD 20), an equal number of saline- and cocainepretreated rats were injected with 0, 7.5, or 15 mg/kg EEDQ and immediately
returned to their home cage. On the test day (PD 21), all rats (n=8 per group)
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Table 2. Design of Experiment 2a
Group

Treatment (Age)
Protection

Preinjection

Pretreatment
Day

Test Day

(PD 18)

(PD 18)

(PD 19)

(PD 21)

Acute Control
Group

Saline

Vehicle

Saline

Cocaine

NonprotectedEEDQ Acute
Control

Saline

EEDQ

Saline

Cocaine

Adrenergic
Protected-EEDQ
Acute Control

Prazosin

EEDQ

Saline

Cocaine

5-HT ProtectedEEDQ Acute
Control

Ritanserin

EEDQ

Saline

Cocaine

Adrenergic/5-HT
Protected-EEDQ
Acute Control

Prazosin+
Ritanserin

EEDQ

Saline

Cocaine

Sensitization
Control Group

Saline

Vehicle

Cocaine

Cocaine

NonprotectedEEDQ
Sensitization

Saline

EEDQ

Cocaine

Coaine

Adrenergic
Protected-EEDQ
Sensitization

Prazosin

EEDQ

Cocaine

Cocaine

5-HT ProtectedEEDQ
Sensitization

Ritanserin

EEDQ

Cocaine

Cocaine

Adrenergic/5-HT
Protected-EEDQ
Sensitization

Prazosin+
Ritanserin

EEDQ

Cocaine

Cocaine
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Table 3. Design of Experiment 2b
Group

Treatment
(Age)
Preinjection (1)

Preinjection (2)

Pretreatment
Day

Test Day

(PD 18)

(PD 18)

(PD 19)

(PD 21)

Acute Control
Group

Saline

Vehicle

Saline

Cocaine

Sensitization
Control Group

Saline

Vehicle

Cocaine

Cocaine

Adrenergic/5-HT
Antagonist Acute
Control

Prazosin+
Ritanserin

Vehicle

Saline

Cocaine

Adrenergic/5-HT
Antagonist
Sensitization

Prazosin+
Ritanserin

Vehicle

Cocaine

Cocaine

were injected with 20 mg/kg cocaine and placed in activity chambers for 120 min.
The design of Experiment 3 is shown in Table 4.
Experiment 4a: The Use of 5-HT and/or α1-Adrenergic Receptor
Protection to Assess the Effects of EEDQ on the Expression of
One-Trial Cocaine-Induced Behavioral Sensitization
On the pretreatment day (PD 19), rats were injected with saline or 30
mg/kg cocaine and placed in activity chambers for 30 min. On the preinjection
day, which occurred 24 h later (PD 20), rats received a protection injection of
prazosin (25 mg/kg), ritanserin (3 mg/kg), prazosin+ritanserin, or saline in the
home cage. After 30 min, rats received a preinjection of EEDQ (15 mg/kg). A
separate control group received a protection injection of saline and a preinjection

50

Table 4. Design of Experiment 3
Group

Treatment (Age)
Pretreatment Day

Preinjection

Test Day

(PD 19)

(PD 20)

(PD 21)

Acute Control
Group

Saline

Vehicle

Cocaine

Sensitization
Control Group

Cocaine

Vehicle

Cocaine

7.5 mg/kg EEDQ
Acute Control

Saline

7.5 mg/kg EEDQ

Cocaine

7.5 mg/kg EEDQ
Sensitization

Cocaine

7.5 mg/kg EEDQ

Cocaine

15 mg/kg EEDQ
Acute Control

Saline

15 mg/kg EEDQ

Cocaine

15 mg/kg EEDQ
Sensitization

Cocaine

15 mg/kg EEDQ

Cocaine

of vehicle. On the test day (PD 21), all rats (n=8 per group) were injected with 20
mg/kg cocaine and placed in activity chambers for 120 min. The design of
Experiment 4a is shown in Table 5.
Experiment 4b: Effects of Ritanserin and Prazosin on the
Expression of One-Trial Cocaine Sensitization
Another four group experiment was conducted to determine whether the
protection treatments affected the locomotor activity of nonEEDQ-treated rats.
On the pretreatment day, which occurred 24 h later (PD 19), half of the rats in
each group received saline and the other half received 30 mg/kg cocaine.
Immediately afterwards, rats were placed in activity chambers for 30 min and
distance traveled was recorded. On the preinjection day (PD 20), rats first
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received an injection of saline or prazosin+ritanserin in the home cage. After 30
min, all rats received a preinjection of vehicle. On the test day (PD 21), all rats
(n=8 per group) were injected with 20 mg/kg cocaine and placed in activity
chambers for 120 min. The design of Experiment 4b is shown in Table 6.
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Table 5. Design of Experiment 4a
Group

Treatment
(Age)
Pretreatment
Day

Protection

Preinjection

Test Day

(PD 19)

(PD 20)

(PD 20)

(PD 21)

Acute Control
Group

Saline

Saline

Vehicle

Cocaine

NonprotectedEEDQ Acute
Control

Saline

Saline

EEDQ

Cocaine

Adrenergic
Protected-EEDQ
Acute Control

Saline

Prazosin

EEDQ

Cocaine

5-HT ProtectedEEDQ Acute
Control

Saline

Ritanserin

EEDQ

Cocaine

Adrenergic/5-HT
Protected-EEDQ
Acute Control

Saline

Prazosin+
Ritanserin

EEDQ

Cocaine

Sensitization
Control Group

Cocaine

Saline

Vehicle

Cocaine

NonprotectedCocaine
EEDQ Sensitization

Saline

EEDQ

Coaine

Adrenergic
Protected-EEDQ
Sensitization

Prazosin

EEDQ

Cocaine

5-HT ProtectedCocaine
EEDQ Sensitization

Ritanserin

EEDQ

Cocaine

Adrenergic/5-HT
Protected-EEDQ
Sensitization

Prazosin+
Ritanserin

EEDQ

Cocaine

Cocaine

Cocaine
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Table 6. Design of Experiment 4b
Group

Treatment
(Age)

Pretreatment
Day

Preinjection
(1)

Preinjection (2) Test Day

(PD 19)

(PD 20)

(PD 20)

(PD 21)

Acute Control Group Saline

Saline

Vehicle

Cocaine

Sensitization Control Cocaine
Group

Saline

Vehicle

Cocaine

Adrenergic/5-HT
Antagonist Acute
Control

Saline

Prazosin+
Ritanserin

Vehicle

Cocaine

Adrenergic/5-HT
Antagonist
Sensitization

Cocaine

Prazosin+
Ritanserin

Vehicle

Cocaine

Data Analysis
To statistically analyze data from both the pretreatment and test days,
distance traveled data was analyzed using one-way or factorial analyses of
variance (ANOVA) depending on experiment. For example, the test day of
Experiment 2a was analyzed using a 5 × 2 × 12 (preinjection × pretreatment ×
time block) mixed factorial ANOVA, with the preinjection and pretreatment
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variables being between-subject factors and time block being a within-subject
repeated measures factor. The Huynh-Feldt epsilon statistic was used to adjust
degrees of freedom when the assumption of sphericity was violated (Huynh &
Feldt, 1976), as determined by Mauchly’s test of sphericity. Corrected degrees of
freedom were rounded to the nearest whole number. When further analyzing
statistically significant higher order interactions, the mean square error terms
(i.e., MSerror) used for the Tukey calculations was based on separate one-way
ANOVAs at each time block.
Litter effects were minimized by assigning no more than one subject from
each litter to a particular group (for a discussion of litter effects, see Zorrilla,
1997). Young rats do not typically exhibit sex differences after psychostimulant
treatment (Bowman, Blatt, & Kuhn, 1997; Frantz, Babcock, & Van Hartesveldt,
1996; McDougall et al., 2013; Snyder, Katovic, & Spear, 1998), so sex was not
included as a factor in the statistical analysis.
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CHAPTER ELEVEN
RESULTS

Experiment 1: Effects of EEDQ on the Induction of One-Trial
Cocaine-Induced Behavioral Sensitization
Pretreatment Day
On the pretreatment day, rats given cocaine (M = 7439.16 cm, SEM =
716.08) had greater locomotor activity than rats given saline (M = 2639.40 cm,
SEM = 392.53) (Figure 1, upper graph) [Drug effect, F(1,47)=36.76, p<0.001].
EEDQ treatment did not significantly affect locomotion, although a nonsignificant
decline in locomotor activity was observed in rats treated with the higher dose of
EEDQ (15 mg/kg).
Test Day
On the test day, locomotor sensitization was evident (Figure 1, lower graph)
since rats in the 0 mg/kg EEDQ-sensitization group had significantly greater
locomotor activity than rats in the 0 mg/kg EEDQ-acute control group
[Preinjection × Drug Interaction, F(2,47)=5.90, p<0.01; and Tukey tests,
p<0.001]. Both the low (7.5 mg/kg) and high doses (15 mg/kg) of EEDQ
significantly attenuated sensitized locomotor activity [Tukey tests, p<0.05]. A
separate Preinjection × Time Block ANOVA comparing only the sensitized
groups showed that EEDQ significantly reduced locomotor activity during time
blocks 1-9 [Preinjection × Time Block interaction, F(7,76)=2.84, p<0.05; and
Tukey tests, p<0.05].
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Experiment 2a: The Use of 5-HT and/or α1-Adrenergic Receptor
Protection to Assess the Effects of EEDQ on the
Induction of One-Trial Cocaine-Induced
Behavioral Sensitization
Pretreatment Day
On the pretreatment day, rats that received cocaine (M = 6361.51 cm, SEM
= 466.18) showed significantly more locomotor activity than rats given saline (M
= 2763.78 cm, SEM = 345.09) (Figure 2, upper graph) [Drug main effect,
F(1,70)= 42.28, p<0.001]. Treatment with prazosin, ritanserin, and EEDQ did not
significantly affect locomotor activity on the pretreatment day.
Test Day
On the test day, it is clear that sensitization occurred since cocainepretreated rats in the Sal-DMSO group (i.e., the Sensitization Control group) had
significantly more locomotor activity counts than saline-pretreated rats in the SalDMSO group (i.e., the Acute Control group) (right panels, Figure 2) [Preinjection
× Drug interaction, F(4,70)=3.62, p<0.05; and Tukey tests, p<0.05]. Among the
saline-pretreated groups, EEDQ did not affect locomotion. Among the cocainepretreated groups, EEDQ significantly reduced locomotor activity, with the
decline being most evident in the Praz-EEDQ group [Tukey tests, p<0.05].
Overall, both the Preinjection and Drug variables interacted with time block to
affect behavior (left panels, Figure 2) [Preinjection × Time Block interaction,
F(19,333)=3.35, p<0.001; Drug × Time Block interaction, F(5,333)=3.08, p<0.05].
A separate analysis of only the cocaine-pretreated groups (i.e., the Sensitization
groups) showed that EEDQ significantly reduced locomotor activity on time
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blocks 1–7 relative to the DMSO controls (lower graph, left panel, Figure 2)
[EEDQ × Time Block interaction, F(4,162)=8.49, p<0.001; and Tukey tests,
p<0.05].
Experiment 2b: Effects of Ritanserin and Prazosin on the
Induction of One-Trial Cocaine Sensitization
Pretreatment Day
Rats that received cocaine (M = 6573.22 cm, SEM = 540.71) showed
significantly more locomotor activity than rats given saline (M = 1964.36 cm, SEM
= 318.22) (Figure 3, upper graph) [Drug main effect, F(1,23)= 76.48, p<0.001].
Locomotor activity was not significantly affected by combined treatment with
prazosin and ritanserin.
Test Day
On the test day, sensitization was not observed because cocaine-pretreated
rats in the saline group (i.e., the Sensitization Control group; M = 45110.70 cm,
SEM = 7419.72) exhibited only marginally more locomotor activity than salinepretreated rats in the saline group (i.e., the Acute Control group; M = 26541.95
cm, SEM = 6093.54) [Preinjection × Drug interaction, F(1,20)= 3.56, p=0.074]
(lower graph, right panels, Figure 3). Combined treatment with the two
antagonists did not affect locomotor activity; however, there was a trend for
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Figure 1. Experiment 1. Mean distance traveled (±SEM) on the pretreatment and
test day. On the preinjection day (PD 18), rats were injected with EEDQ (0, 7.5,
or 15 mg/kg). On pretreatment day (PD 19), rats were injected with saline or 30
mg/kg cocaine, immediately followed by 30 min of behavioral assessment. On
the test day (PD 21), all rats were injected with 20 mg/kg cocaine, immediately
followed by 120 min of behavioral assessment. * Significantly different from the 0
mg/kg EEDQ-Saline group (acute control group; open circles and open bars). †
Significantly different from the 0 mg/kg EEDQ-cocaine group (cocaine alone
group; filled circles and black bars).
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Figure 2. Experiment 2a. Mean distance traveled (±SEM) on the pretreatment
and test day. On the preinjection day (PD 18), rats were injected with prazosin (5
mg/kg), ritanserin (5 mg/kg), prazosin+ritanserin, or saline in the home cage.
After 30 min, rats received a preinjection of EEDQ (15 mg/kg). On the
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine,
immediately followed by 30 min of behavioral assessment. On the test day (PD
21), all rats were injected with 20 mg/kg cocaine, immediately followed by 120
min of behavioral assessment. * Significantly different from the Saline-DMSO
Acute Control group (open bar). † Significantly different from the Saline-DMSO
Sensitization group (filled bar, filled circles).
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prazosin+ritanserin to enhance the locomotor activity of saline-pretreated rats
and depress the locomotion of cocaine-pretreated rats.
Experiment 3: Effects of EEDQ on the Expression of One-Trial
Cocaine-Induced Behavioral Sensitization
On the pretreatment day, rats given cocaine (M = 8054.65 cm, SEM =
343.22) had greater locomotor activity than rats given saline (M = 2118.44 cm,
SEM = 217.77) [t(46)= 14.60, p<0.001]. On the test day, locomotor sensitization
was apparent since the 0 mg/kg EEDQ-sensitization group exhibited significantly
more locomotor activity than the 0 mg/kg EEDQ-acute control group [Preinjection
× Drug Interaction, F(2,47)= 5.74, p<0.01; and Tukey tests, p<0.05] (Figure 4).
Both the low (7.5 mg/kg) and high (15 mg/kg) doses of EEDQ significantly
attenuated locomotor activity, because the 7.5 mg/kg EEDQ-sensitization group
and the 15 mg/kg EEDQ-sensitization group had significantly less locomotor
activity than the 0 mg/kg EEDQ-sensitization group [Preinjection × Drug
Interaction]. Moreover, the EEDQ-sensitization groups were not different from the
acute control group.
Experiment 4a: The Use of 5-HT and/or α1-Adrenergic Receptor
Protection to Assess the Effects of EEDQ on the
Expression of One-Trial Cocaine-Induced
Behavioral Sensitization
On the pretreatment day, rats that received cocaine (M = 7691.17 cm, SEM
= 331.28) had significantly more locomotor activity than rats given saline (M =
2593.23 cm, SEM = 219.26) [t(78)= 12.832, p<0.001]. On the test day, locomotor
sensitization was not apparent since cocaine-pretreated rats (M = 28456.66 cm,
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SEM = 1707.44) exhibited only marginally more locomotor activity than salinepretreated rats (M = 24026.85 cm, SEM = 1702.95) [Preinjection main effect,
F(1,70)= 3.74, p=0.057] (right panels, Figure 5). A separate statistical analysis
comparing only the saline-pretreated and cocaine-pretreated Sal-DMSO groups
also indicated an absence of behavioral sensitization. Neither EEDQ or the
protection treatments significantly affected performance on the test day
[Preinjection main effect, F(4,70)= 2.49, p=0.052].
Experiment 4b: Effects of Ritanserin and Prazosin on the
Expression of One-Trial Cocaine Sensitization
On the pretreatment day, rats given cocaine (M = 8214.45 cm, SEM =
548.58) had significantly more locomotor activity than rats that received saline (M
= 2788.30 cm, SEM = 383.31) [t(22)= 8.11, p<0.001]. On the test day, locomotor
sensitization was evident since rats in the saline-sensitization group had
significantly greater locomotor activity than rats in the saline-acute control group
[Preinjection × Drug interaction, F(1,20)= 6.53, p<0.05] (right panels, Figure 6).
In addition, sensitized rats preinjected with prazosin and ritanserin had
significantly less locomotor activity than those that received a preinjection of
saline [Preinjection × Drug interaction]. None of the interactions involving the
time block variable were statistically significant.
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Figure 3. Experiment 2b. Mean distance traveled (±SEM) on the pretreatment
and test day. On the preinjection day (PD 18), rats were injected with
prazosin+ritanserin or saline in the home cage. After 30 min, rats received an
injection of vehicle. On the pretreatment day (PD 19), rats were injected with
saline or 30 mg/kg cocaine, immediately followed by 30 min of behavioral
assessment. On the test day (PD 21), all rats were injected with 20 mg/kg
cocaine, immediately followed by 120 min of behavioral assessment. *
Significantly different from the Saline control group (open bar).
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Figure 4. Experiment 3. Mean Distance traveled (±SEM) on the test day. On
the pretreatment day (PD19), rats were injected with saline or 30 mg/kg
cocaine, immediately followed by 30 min of behavioral assessment. On the
preinjection day (PD 20), rats were injected with EEDQ (0, 7.5, or 15 mg/kg) in
the home cage. On the test day (PD 21), all rats were challenged with 20
mg/kg cocaine followed immediately by 120 min of behavioral assessment. *
Significantly different from 0 mg/kg EEDQ-Saline group (acute control group;
open circles and open bars). † Significantly different from the 0 mg/kg EEDQcocaine group (cocaine alone group; filled circles and black bars).
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Figure 5. Experiment 4a. Mean distance traveled (±SEM) on the test day. On the
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine,
immediately followed by 30 min of behavioral assessment. On the preinjection
day (PD 20), rats were injected with prazosin (5 mg/kg), ritanserin (5 mg/kg),
prazosin+ritanserin, or saline in the home cage. After 30 min, rats received a
preinjection of EEDQ (15 mg/kg). On the test day (PD 21), all rats were injected
with 20 mg/kg cocaine, immediately followed by 120 min of behavioral
assessment.
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Figure 6. Experiment 4b. Mean distance traveled (±SEM) on the test day. On the
pretreatment day (PD 19), rats were injected with saline or 30 mg/kg cocaine,
immediately followed by 30 min of behavioral assessment. On the preinjection
day (PD 20), rats were injected with prazosin+ritanserin or saline in the home
cage. After 30 min, rats received an injection of vehicle. On the test day (PD 21),
all rats were injected with 20 mg/kg cocaine, immediately followed by 120 min of
behavioral assessment. * Significantly different from the Saline control group
(open bar). † Significantly different from the Saline Sensitization group (filled
bar).
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CHAPTER TWELVE
DISCUSSION

Prior to this thesis, research examining the mechanisms underlying
cocaine-induced one-trial behavioral sensitization in preweanling rats was
scarce (e.g., see McDougall et al., 2016; Mohd-Yusof et al., 2014; 2016);
however, multiple studies using adult rats indicated that dopaminergic,
serotonergic, and adrenergic receptor systems are involved in the mediation
of behavioral sensitization (Auclair et al., 2004; O’Neill et al., 1999;
Vanderschuren et al., 2003). Behavioral and neurochemical data using
preweanling rats suggest that selective protection from the nonspecific
irreversible antagonist EEDQ could be useful for investigating the role of
individual receptor types in behavioral sensitization (McDougall et al., 2016).
Therefore, in the present thesis I used EEDQ in conjunction with selective
protection experiments to examine whether the serotonergic and adrenergic
receptor systems mediate the induction and expression of cocaine-induced
one-trial behavioral sensitization in preweanling rats.
Results from this thesis showed that cocaine was able to induce onetrial behavioral sensitization in preweanling rats. By administering EEDQ
prior to either the pretreatment day or the test day, it was apparent that
general receptor inactivation blocked both the induction and expression of
cocaine-induced one-trial behavioral sensitization. Importantly, administering
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prazosin and ritanserin prior to EEDQ treatment did not protect the induction
or expression of behavioral sensitization, which suggests that serotonergic
and adrenergic receptors do not mediate cocaine-induced sensitized
responding in preweanling rats. This negative result indicates that some
other receptor type, or a combination of redundant receptor systems,
mediates the induction and expression of behavioral sensitization (see also
White et al., 1998).
Some findings from this study were unexpected. For example, it was
concerning that cocaine did not induce a statistically significant sensitized
response in Experiments 2b and 4a. In the case of Experiment 2b, there
were only six subjects per group, as opposed to the eight subjects per group
that we normally use. This lack of power may have been responsible for the
inability to detect behavioral sensitization. Interestingly, the magnitude of the
effect size between the Acute Control group and the Sensitization group of
Experiment 2b is similar to, if not greater than, experiments in which
statistically significant behavioral sensitization was observed. For example,
the effect size magnitude was 18568.75 cm in Experiment 2b, which resulted
in a nonsignificant difference; whereas, the effect size magnitude between
the Acute Control and Sensitization group of Experiment 4b was 17137.88
cm, which was sufficient for a statistically significant effect. In the case of
Experiment 4a, the reason for the marginal sensitized responding is more
unclear. Perhaps the fact that this experiment examined the expression
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(rather than the induction) of behavioral sensitization was responsible for the
weakened sensitization effect. More specifically, the nature of the expression
paradigm may have led to increased stress on the control animals (i.e., the
induction paradigm requires fewer injections on PD 20 and 21 than the
expression paradigm), which may have affected our ability to detect cocaineinduced behavioral sensitization. Indeed, stress-induced behavioral
sensitization is a well known phenomenon that can be initiated by the
injection protocol itself (for a review, see Robinson & Becker, 1986). That
being said, Experiment 4b was also an expression experiment, with the
same number and timing of injections, and statistically significant behavioral
sensitization was achieved. Therefore, it is uncertain why cocaine-induced
behavioral sensitization was not evident in Experiment 4a. In the same
experiment, EEDQ did not block behavioral sensitization; however, since a
statistically significant sensitized response did not occur, it is reasonable to
argue that EEDQ could not block a phenomenon that was not present. Even
so, close examination of the data reveals that EEDQ did not appear to cause
a robust decline in the locomotor activity of the “sensitization” groups.
Finally, it is concerning that prazosin and ritanserin affected the
locomotor activity and sensitized responding of cocaine-treated rats
independent of the actions of EEDQ (see Experiments 2b and 4b). The
results of Experiment 2a suggest that neither the serotonergic or adrenergic
receptor systems are responsible for one-trial cocaine-induced behavioral
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sensitization, because protecting these specific receptors from EEDQ failed
to keep behavioral sensitization intact. The results of Experiment 2b and 4b
challenge this conclusion, as the absence of behavioral sensitization may
have been due to the drugs used to protect the serotonergic and adrenergic
receptors. It is unclear whether it was prazosin or ritanserin that weakened
sensitized responding, since these drugs were co-administered in the control
experiments (2b and 4b). Testing the effects of prazosin or ritanserin alone
on cocaine-induced one-trial behavioral sensitization would resolve this
issue. Additional improvements for future studies would include using
different serotonergic and adrenergic antagonists, as well as novel methods
of receptor protection.
The finding that prazosin and ritanserin caused prolonged changes in
cocaine-induced behavioral sensitization is interesting in its own right and
deserves consideration. The most obvious possibility is that these
serotonergic and adrenergic compounds altered the functioning of the
dopaminergic system, which resulted in the observed changes in locomotor
activity. For example, 5-HT2 receptor antagonism by ritanserin potentiates
amphetamine-induced dopamine release in adult rats (Pehek & Bi, 1997). In
addition, prazosin decreases dopamine transmission in the reward pathway
(Zhang & Kosten, 2005). Therefore, ritanserin and prazosin may impact both
cocaine-induced locomotor activity and behavioral sensitization by altering
normal dopaminergic functioning.
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In addition to the uncertainty regarding the effects of prazosin and
ritanserin on behavioral sensitization, we did not demonstrate that these
drugs protected adrenergic and serotonergic receptors from the alkylating
effects of EEDQ. Although previous receptor binding experiments show that
5 mg/kg prazosin and 1 mg/kg ritanserin protect adrenergic and serotonergic
receptors, respectively, from alkylation by EEDQ, the animals used in these
studies were adult rats (Giorgi & Biggio, 1990; Kettle, Cheetham, Martin,
Prow, & Heal, 1999). Given the many ontogenetic differences involving the
serotonergic and adrenergic receptor systems (e.g., Auclair et al., 2004;
Drouin et al., 2002), there is the possibility that these compounds may not
have the same protective effects in preweanling rats. In the future, it would
be advantageous to conduct a receptor binding study to confirm the
protective effects of prazosin and ritanserin in preweanling rats. In addition,
the combined use of these drugs, in conjunction with EEDQ, may be
producing an effect that interferes with behavioral sensitization. For example,
in Experiments 2b and 4b, it is clear that antagonizing serotonergic and
adrenergic receptors reduces locomotor activity. This evidence indicates that
serotonergic and adrenergic receptor stimulation is necessary for the
induction and expression of behavioral sensitization; however, the results of
Experiments 2a and 4a do not support this conclusion. Therefore, the
combined effects of ritanserin, prazosin, and EEDQ should be further
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examined, and in future experiments, different drugs that do not have
complex interactions should be considered.
It is well established that the neural mechanisms underlying behavioral
sensitization differ depending on the psychostimulant drug being used (e.g.,
cocaine vs. amphetamine; see Vanderschuren & Kalivas, 2000; White et al.,
1998). For example, Auclair et al. (2004) reported that serotonergic and
adrenergic receptor antagonists prevent the induction and expression of
amphetamine-induced behavioral sensitization in adult mice; whereas, I
found that the same drugs did not affect cocaine-induced behavioral
sensitization in preweanling rats. The reason for such psychostimulantspecific effects may lie in the mechanism of action for each drug. In general,
amphetamine-like compounds affect brain function by enhancing the
transmission of monamines like serotonin, norepinephrine, and dopamine
(Shi, Pun, Zhang, Jones, & Bunney, 2000). Specifically, amphetamine blocks
the reuptake of monoamines, while also increasing cytoplasmic dopamine
concentrations via reverse receptor transport (Fleckenstein & Hanson,
2003). In contrast, cocaine increases extracellular monoamine levels through
the sole mechanism of blocking monoamine reuptake transporters (Meyer &
Quenzer, 2005; Vanderschuren & Kalivas, 2000).
Auclair et al. (2004) also reported that serotonergic and adrenergic
receptor antagonists block the induction and expression of cocaine-induced
behavioral sensitization. In the Auclair et al. (2004) experiment, adult mice
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were used as opposed to preweanling rats. These discrepant results leave
open the possibility that there are ontogenetic or species-based differences
in the mechanisms mediating behavioral sensitization. Although species
differences in behavioral sensitization are seldom reported, pronounced agedependent differences in sensitized responding are well-established (for a
review, see Tirelli et al., 2003). For example, one-trial behavioral
sensitization persists for months in adult rats, while only lasting a few days in
preweanling rats (McDougall et al., 2009; Robinson et al., 1982; Valjent et
al., 2010). In addition, drug-environment associations are necessary for the
one-trial behavioral sensitization of adult rats (Weiss et al., 1989), while
environmental context does not influence the one-trial sensitized responding
of preweanling rats (McDougall et al., 2009). Finally, D1-like antagonists
block the induction of one-trial behavioral sensitization in adult rats, but not in
preweanling rats (Mattingly et al., 1991; Mohd-Yusof et al., 2014; Kuribara,
1995; Valjent et al., 2010).
In addition to ontogenetic and species-based differences in the
mechanisms underlying behavioral sensitization, there also appear to be
ontogenetic differences in the actions of EEDQ. For example, EEDQ blocks
behavioral sensitization in preweanling rats and locomotor activity in adults,
but this alkylating agent does not reduce locomotor activity in the younger
age group (Der-Ghazarian et al., 2014; McDougall, Valentine, Gonzalez,
Humphrey, Widarma, & Crawford, 2014). These findings suggest that the
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mechanisms mediating locomotor activity in preweanling rats are resistant to
EEDQ, while the mechanisms mediating behavioral sensitization are not.
The inability of EEDQ to block the locomotor activity of preweanling rats is
interesting, and may be due to a compensatory mechanism involving an
excess of high affinity D2-like receptors that is absent in older animals
(McDougall et al., 2014). Consistent with this explanation, preweanling rats
have a higher percentage of high affinity striatal D2-like receptors (i.e., D2High
receptors) than adolescent or adult animals (McDougall et al., 2015).
Although thousands of studies have examined the neural bases of
behavioral sensitization, it remains unclear which receptor systems are
important for the induction and expression of cocaine-induced behavioral
sensitization. Despite contradictory evidence, it is still possible that
dopaminergic, serotonergic, and adrenergic receptor systems all play a role
in behavioral sensitization. In the typical study, investigation of these
receptor systems has been restricted to antagonism or stimulation of
individual receptor types. Instead, it is probable that many neurotransmitter
systems work simultaneously, and perhaps redundantly, to mediate the
complex process that is behavioral sensitization. Since it is likely that there
are many neurotransmitter systems involved in the mediation of behavioral
sensitization, antagonizing only a single receptor type may not have a great
effect on the overall sensitization process. In other words, when one
particular neurotransmitter system is antagonized, another neurotransmitter
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system may compensate in order to keep the behavior intact. For this
reason, it will be necessary to study the combined actions of multiple
receptor systems on behavioral sensitization, instead of assessing each
system independently.
Although the dopamine, serotonin, and noradrenergic neurotransmitter
systems may interact to mediate behavioral sensitization, it remains possible
that other receptor types are also involved with this complex behavior. In
terms of the present study, EEDQ may have blocked behavioral sensitization
by affecting a receptor type that was not protected from alkylation. In addition
to irreversibly antagonizing dopaminergic, serotonergic, and adrenergic
receptors, EEDQ inhibits the release and high-affinity uptake of acetylcholine
in the hippocampus (Vickroy & Malphurs, 1994). Therefore, besides
examining the combined effects of monoamine neurotransmitter systems on
behavioral sensitization, future experiments should also consider the roles
played by other neural mechanisms.
In conclusion, EEDQ blocks the induction and expression of one-trial
cocaine-induced behavioral sensitization. The protection experiments using
ritanserin and prazosin indicate, but do not conclusively show, that the
serotonergic and adrenergic receptor systems do not mediate the induction
and expression of one-trial cocaine-induced behavioral sensitization in
preweanling rats. Considering both past and present results, the most
harmonious conclusion is that multiple receptor systems (i.e., dopaminergic,
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serotonergic, adrenergic, etc.) work in unison to produce the complex
phenomenon of behavioral sensitization.
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